ZLAB has 36-month beta value of 0.95. Analysts have mixed views on the stock, with 7 analysts rating it as a “buy,” 4 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for ZLAB is 108.40M, and currently, short sellers hold a 4.59% ratio of that float. The average trading volume of ZLAB on June 04, 2025 was 1.16M shares.
ZLAB) stock’s latest price update
Zai Lab Limited ADR (NASDAQ: ZLAB) has experienced a rise in its stock price by 15.97 compared to its previous closing price of 31.13. However, the company has seen a gain of 19.22% in its stock price over the last five trading days. businesswire.com reported 2025-06-02 that SHANGHAI & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that updated data from an ongoing, global Phase 1a/1b clinical trial (NCT06179069) evaluating zocilurtatug pelitecan, or ZL-1310, the Company’s potential first-in-class, Delta-like ligand (DLL3) antibody-drug conjugate (ADC) for patients with extensive-stage small cell lung cancer (ES-SCLC), will be presented today during a poster session at the 2025 American Society of Clinical Oncology (AS.
ZLAB’s Market Performance
ZLAB’s stock has risen by 19.22% in the past week, with a monthly rise of 16.64% and a quarterly rise of 0.53%. The volatility ratio for the week is 3.44% while the volatility levels for the last 30 days are 3.37% for Zai Lab Limited ADR The simple moving average for the past 20 days is 17.25% for ZLAB’s stock, with a 28.06% simple moving average for the past 200 days.
Analysts’ Opinion of ZLAB
Many brokerage firms have already submitted their reports for ZLAB stocks, with Scotiabank repeating the rating for ZLAB by listing it as a “Sector Outperform.” The predicted price for ZLAB in the upcoming period, according to Scotiabank is $55 based on the research report published on March 07, 2025 of the current year 2025.
BofA Securities, on the other hand, stated in their research note that they expect to see ZLAB reach a price target of $36.10, previously predicting the price at $29. The rating they have provided for ZLAB stocks is “Neutral” according to the report published on March 03rd, 2025.
Morgan Stanley gave a rating of “Overweight” to ZLAB, setting the target price at $47.50 in the report published on December 14th of the previous year.
ZLAB Trading at 14.70% from the 50-Day Moving Average
After a stumble in the market that brought ZLAB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -9.23% of loss for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at ZLAB starting from Chen Yajing, who proposed sale 9,618 shares at the price of $30.00 back on Jun 02 ’25. After this action, Chen Yajing now owns shares of Zai Lab Limited ADR, valued at $288,540 using the latest closing price.
Du Ying, the Chairperson & CEO of Zai Lab Limited ADR, sale 50,000 shares at $28.57 during a trade that took place back on May 13 ’25, which means that Du Ying is holding 479,851 shares at $1,428,650 based on the most recent closing price.
Stock Fundamentals for ZLAB
Current profitability levels for the company are sitting at:
- -0.64 for the present operating margin
- 0.63 for the gross margin
The net margin for Zai Lab Limited ADR stands at -0.6. The total capital return value is set at -0.31. Equity return is now at value -32.05, with -23.32 for asset returns.
Based on Zai Lab Limited ADR (ZLAB), the company’s capital structure generated 0.19 points at debt to capital in total, while cash flow to debt ratio is standing at -0.97. The debt to equity ratio resting at 0.24. The interest coverage ratio of the stock is -80.56.
Currently, EBITDA for the company is -234.57 million with net debt to EBITDA at 2.39. When we switch over and look at the enterprise to sales, we see a ratio of 7.72. The receivables turnover for the company is 4.77for trailing twelve months and the total asset turnover is 0.36. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.26.
Conclusion
To put it simply, Zai Lab Limited ADR (ZLAB) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
